17 extractive question-and-answer pairs built from ICMR Standard Treatment Workflow (STW) LUNG CANCER, published by icmr.gov.in. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. 17 of the 17 pairs (100.0%) are explanatory questions and 0 restate a figure. 100.00% of rows pass the corpus quality gate.
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/icmr-standard-treatment-workflow-for-lung-cancer-question-and-answer-dataset/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("icmr-standard-treatment-workflow-for-lung-cancer-question-and-answer-dataset")
df.head()Sign in with Google to download.
Usable for analysis, but expect some cleaning before you rely on it.
Consensus Document on Management of Pancreatic Cancer - Question and Answer Dataset
Economy · 268 rows
ICMR Standard Treatment Workflow for Cataract - Question and Answer Dataset
Economy · 27 rows
Neurology Questions from P a R T N E R S - Question and Answer Dataset
Economy · 107 rows
Beginner's Guide for Systematic Reviews - Question and Answer Dataset
Economy · 407 rows
Annual Report 2015-16 by agriwelfare.gov.in - Question and Answer Dataset
Economy · 1,013 rows
Higher Education in India - Question and Answer Dataset
Economy · 1,594 rows
Gender Policy of NABARD - Question and Answer Dataset
Economy · 14 rows
ICAR Annual Report 2025-26 - Question and Answer Dataset
Economy · 1,101 rows
First 10 of 17 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|
| What are the classifications of metastatic and non-metastatic disease? | Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 2 | comparison | 0.920 | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 1 | page=1,block=11 | 0.700 | valid |
| What defines early localized and locoregionally advanced disease? | Early localized : T1-3, N0-2 Locoregionally advanced : T4, N3 | Early localized : T1-3, N0-2 Locoregionally advanced : T4, N3 Metastatic disease. any T, any N, M1 Concurrent CT+ RT Brain/ symptomatic bone metastases Other visceral metastases EBUS/ EUS ± mediastinoscopy Unfit or patient refuses surgery Pallative radiation; Bisphosphonates for bone metastases Histology Oral TKI or platinum doublet chemotherapy Platinum doublet chemotherapy or chemoimmunotherapy Non- Squamous Squamous carcinoma Mutation +ve Mutation -ve Driver mutation test Platinum doublet chemotherapy or chemoimmunotherapy | 0 | comparison | 0.920 | Early localized : T1-3, N0-2 Locoregionally advanced : T4, N3 Metastatic disease. | 1 | page=1,block=42 | 0.700 | valid |
| What are the classifications for metastatic and non-metastatic diseases? | Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 2 | comparison | 0.920 | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 1 | page=1,block=11 | 0.700 | valid |
| What types of carcinoma can be identified through histopathology? | adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 43 | list | 0.820 | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 1 | page=1,block=4 | ||
| What immunohistochemistry markers are used in the analysis? | TTF 1, p40, synaptophysin/ chromogranin | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 156 | list | 0.820 | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 1 | page=1,block=4 | 0.700 | |
| What factors should be evaluated during a patient's presentation? | Age and comorbidities Performance status | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 377 | list | 0.820 | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 1 | page=1,block=11 | 0.700 | valid |
| What methods are used to evaluate pulmonary reserve? | Effort tolerance • Walk test • Pulmonary function tests (PFT) | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 76 | list | 0.820 | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 1 | page=1,block=25 | 0.700 | valid |
| What techniques are used to examine pleural fluid or perform a biopsy? | Pleural fluid cytology • Pleural biopsy (image guidance if available) | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 293 | list | 0.820 | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 1 | page=1,block=25 | 0.700 | valid |
| What are the important parameters to assess during clinical examination? | Age and comorbidities Performance status | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 377 | list | 0.820 | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 1 | page=1,block=11 | 0.700 | valid |
| What are the symptoms that might persist even after treating pneumonia? | Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 140 | list | 0.820 | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 1 | page=1,block=25 | 0.700 | valid |
Read straight from the file — download or use the API URL for the full dataset.
| 0.700 |
| valid |
| valid |